Immutep IMMP
NASDAQ IMMP
$0.36 -0.01 (-2.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Immutep (IMMP) Total Liabilities (2011 - 2026)

Immutep's (IMMP) quarterly Total Liabilities came in at $15.4 million in Q2 2026, up 80.35% on a YoY basis from $8.5 million in Q2 2025, and down 51.39% quarter-over-quarter from $31.7 million in Q4 2025.

Analysis

Immutep (IMMP) Total Liabilities (2011 - 2026) Analysis & Trends

Immutep (IMMP) has reported Total Liabilities for 16 consecutive years, with $15.4 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Liabilities rose 80.35% year-over-year to $15.4 million; the trailing twelve-month figure through Jun 2026 stood at $15.4 million (up 80.35% YoY), and the FY2026 full-year result was $15.4 million, up 80.35% from the prior year.
  • Total Liabilities retreated to $15.4 million in Q2 2026 per IMMP's latest filing, from $31.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $31.7 million in Q4 2025 and bottomed at $5.3 million in Q4 2023.
  • Historically, Total Liabilities has averaged $10.5 million across 5 years, with a median of $7.3 million in 2023.
  • The sharpest annual moves came in 2022 and 2025: Total Liabilities fell 25.79% in 2022, then surged 392.04% in 2025.
  • Over 5 years, Total Liabilities stood at $6.1 million in 2022, then slipped by 13.4% to $5.3 million in 2023, then increased by 21.55% to $6.4 million in 2024, then soared by 392.04% to $31.7 million in 2025, then plunged by 51.39% to $15.4 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods registered $15.4 million, $31.7 million, and $8.5 million for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Liabilities (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 83.95 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 37.53 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 7.18 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 10.02 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 1.62 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 4.20 Bn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 13.24 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 384.62 Mn
10 Immutep 51.68 Mn 51.68 Mn - 15.42 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15.42 Mn
Dec 31, 2025 31.71 Mn
Jun 30, 2025 8.55 Mn
Dec 31, 2024 6.45 Mn
Jun 30, 2024 7.95 Mn
Dec 31, 2023 5.30 Mn
Jun 30, 2023 7.34 Mn
Dec 31, 2022 6.12 Mn
Jun 30, 2022 5.80 Mn
Dec 31, 2021 8.25 Mn
Jun 30, 2021 6.74 Mn
Dec 31, 2020 11.54 Mn
Jun 30, 2020 8.72 Mn
Dec 31, 2019 10.20 Mn
Jun 30, 2019 11.32 Mn
Jun 30, 2018 10.20 Mn
Dec 31, 2017 7.63 Mn
Jun 30, 2017 6.33 Mn
Mar 31, 2017 5.22 Mn
Dec 31, 2016 6.90 Mn